1297474-29-3

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 1297474-25-9 C₁₄H₁₆O₃ 
• 1297474-23-7 C₁₆H₂₂O₅ 
• 20469-65-2 1-bromo-3,5-dimethoxybenzene 
• 680596-79-6 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane 
• 170011-47-9 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate 

Downstream Products

• 1297474-40-8 C₁₇H₁₆N₂O₃S 
• 1297474-49-7 C₂₉H₂₆N₂O₇S 
• 1297474-51-1 C₂₁H₁₆N₂O₄S 
• 1297474-15-7 2-(4-(7-(3,5-dimethoxyphenyl)-4-oxo-3,4-dihydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)-2-methoxyphenoxy)acetic acid 
• 1297474-16-8 3-(7-(3,5-dimethoxyphenyl)-4-oxo-3,4dihydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)propanoic acid 
• 1297474-31-7 C₁₇H₂₀N₂O₃S 
• 1344674-53-8 2-(4-(3,5-dimethoxyphenyl)cyclohexylidene)-1-(4-iodobenzyl)-1-phenylhydrazine 
• 1344674-31-2 (S)-3-(3,5-dimethoxyphenyl)-9-(4-iodobenzyl)-2,3,4,9-tetrahydro-1H-carbazole 

Relevant academic research and scientific papers

Design and synthesis of novel small molecule CCR2 antagonists: Evaluation of 4-aminopiperidine derivatives

A novel N-(2-oxo-2-(piperidin-4-ylamino)ethyl)-3-(trifluoromethyl)benzamide series of human CCR2 chemokine receptor antagonists was identified. With a pharmacophore model based on known CCR2 antagonists a new core scaffold was designed, analogues of it synthesized and structure-affinity relationship studies derived yielding a new high affinity CCR2 antagonist N-(2-((1-(4-(3-methoxyphenyl)cyclohexyl)piperidin-4-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide.

Aryl extensions of thienopyrimidinones as fibroblast growth factor receptor 1 kinase inhibitors

Optimization of thienopyrimidinone derivatives as FGFR1 kinase inhibitors is being pursued. The present results confirm predictions of computational modeling that an aryl substituent can be introduced at the 2-position in structure 3. The substituent is anticipated to project deeper into the binding site and provide opportunities for enhanced activity and selectivity. The most potent analog reported herein, 13, has a 4-hydroxyphenyl substituent and yields an IC50 of 6 μM for inhibition of phosphorylation by FGFR1 kinase. It was also found that the western anisole-containing substituent in 3 can be replaced by a propionic acid group with no loss in potency and with potentially significant gains in pharmacologically relevant properties.

The catalytic asymmetric Fischer indolization

The first catalytic asymmetric Fischer indolization is reported. In the presence of a 5 mol % loading of a novel spirocyclic chiral phosphoric acid, 4-substituted cyclohexanone-derived phenylhydrazones undergo a highly enantioselective indolization. Efficient catalyst turnover was achieved by the addition of a weakly acidic cation exchange resin, which removes the generated ammonia. The reaction can be conducted under mild conditions and gives various 3-substituted tetrahydrocarbazoles in generally high yields.